COLLIGO-HCM is a global observational study that will conduct observational research of hypertrophic cardiomyopathy (HCM) treatment in real-world clinical practice.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Participant age at Hypertrophic Cardiomyopathy (HCM) diagnosis
Timeframe: Baseline, index date
Participant age at mavacamten treatment initiation
Timeframe: Index date
Participant sex
Timeframe: Baseline
Participant race/ethnicity
Timeframe: Baseline
Participant insurance coverage
Timeframe: Baseline
Participant employment status
Timeframe: Baseline
Participant educational level
Timeframe: Baseline
Date of Hypertrophic Cardiomyopathy (HCM) diagnosis
Timeframe: Baseline or index date
Participant body mass index (BMI) at Hypertrophic Cardiomyopathy (HCM) diagnosis
Timeframe: Baseline or index date
Hypertrophic Cardiomyopathy (HCM) subtype at diagnosis
Timeframe: Baseline or index date
Participant echocardiogram (ECHO) parameters at Hypertrophic Cardiomyopathy (HCM) diagnosis
Timeframe: Baseline or index date, and up to 33 months
Participant New York Heart Association (NYHA) class
Timeframe: Baseline or index date, and up to 33 months
Reason/trigger for initiating the path to Hypertrophic Cardiomyopathy (HCM) diagnosis
Timeframe: Baseline
Date of reason/trigger that initiated the path to Hypertrophic Cardiomyopathy (HCM) diagnosis
Timeframe: Baseline
Participant height
Timeframe: Baseline
Participant weight
Timeframe: Baseline
Participant blood pressure
Timeframe: Baseline
Participant heart rate
Timeframe: Baseline
Participant Hypertrophic Cardiomyopathy (HCM) symptoms
Timeframe: Baseline or index date, and up to 33 months
European participant CYP2C19 genotype
Timeframe: Baseline or index date, and up to 33 months
Participant family history of Hypertrophic Cardiomyopathy (HCM)
Timeframe: Baseline or index date
Participant family history of obstructive Hypertrophic Cardiomyopathy o(HCM)
Timeframe: Baseline or index date
Participant family history of sudden cardiac death (SCD)
Timeframe: Baseline or index date
Participant smoking status
Timeframe: Baseline or index date
Participant alcohol use
Timeframe: Baseline or index date
Participant recreational drug use
Timeframe: Baseline or index date
Participant involvement in a Hypertrophy Cardiomyopathy (HCM) randomized clinical trial (RCT)
Timeframe: Baseline or index date, and up to 33 months
Participant cardiovascular (CV) and CV-related comorbidities
Timeframe: Baseline and index date
Participant non-cardiovascular (CV)-related comorbidities
Timeframe: Baseline or index date
Participant electrocardiogram (ECG) rhythm results
Timeframe: Baseline or index date
Participant cardiac magnetic resonance imaging (MRI) results
Timeframe: Baseline or index date
Participant N-terminal pro-B-type natriuretic peptide (NT-proBNP) results
Timeframe: Baseline or index date
Participant cardiac troponin results
Timeframe: Baseline or index date
Participant cardiopulmonary exercise test (CPET) results
Timeframe: Baseline or index date
Participant cardiac monitoring results
Timeframe: Baseline or index date
Participant exercise test results
Timeframe: Baseline or index date
Participant blood creatine levels
Timeframe: Baseline or index date
Participant cardiovascular (CV) events
Timeframe: Baseline
Type of procedures received by participants
Timeframe: Baseline or index date, and up to 33 months
Cardiovascular treatments prescribed to participants
Timeframe: Baseline, and up to 33 months
Date of mavacamten prescription
Timeframe: Baseline
Date of mavacamten treatment initiation
Timeframe: Index date
Date of mavacamten dosage change
Timeframe: Up to 33 months
Reason for mavacamten dosage change
Timeframe: Up to 33 months
Occurrence of mavacamten stable dose (a period of 6-months with the same dose)
Timeframe: Up to 33 months
Dates of follow-up after mavacamten treatment initiation
Timeframe: Up to 33 months
Date of mavacamten treatment interuption or discontinuation
Timeframe: Up to 33 months
Reason for mavacamten treatment interuption or discontinuation
Timeframe: Up to 33 months
Supportive care provided to participants
Timeframe: Up to 33 months
Heath care resource utilization (HCRU)
Timeframe: Up to 33 months
Hypertrophic Cardiomyopathy (HCM) symptom improvement post mavacamten treatment initiation
Timeframe: Up to 33 months